NCI-2023-06607

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®662 in Monotherapy or in Combination with Pembrolizumab in Advanced Solid Tumors

In this Phase 1 study, researchers are investigating a new treatment called XmAb®662 in patients with advanced solid tumors. Participants with these types of cancers are eligible to take part in the study. The research aims to not only evaluate the safety and pharmacokinetics of XmAb®662 but also its effectiveness, especially when used alone or in combination with Pembrolizumab, an immunotherapy medication.

Phase 1 study: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

pharmacokinetics: Pharmacokinetics studies how medicines move around in the body, including how they are absorbed, distributed, broken down, and removed.

immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05996445

Clinical Trial Site: Sinai

To see all available clinical trials click here.